Evidence map›Paper›PMID 28628637›Full record

ArticlePloS one2017

Survival, bacterial clearance and thrombocytopenia are improved in polymicrobial sepsis by targeting nuclear transport shuttles.

Ruth Ann Veach, Yan Liu, Jozef Zienkiewicz, Lukasz S Wylezinski, Kelli L Boyd, James L Wynn, Jacek Hawiger

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Advances and transgressions of nuclear transport checkpoint inhibitors.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ruth Ann VeachImmunotherapy Program at Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Yan LiuImmunotherapy Program at Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Jozef ZienkiewiczImmunotherapy Program at Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Lukasz S WylezinskiImmunotherapy Program at Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Kelli L BoydDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
James L WynnDepartment of Pediatrics, University of Florida, Gainesville, Florida, United States of America.
Jacek HawigerImmunotherapy Program at Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.ORCID http://orcid.org/0000-0003-2721-6859
Vanderbilt University · USUniversity of Florida · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
The Role of the Inflammasome in Neonatal SepsisK08GM106143 · NIGMS · VANDERBILT UNIVERSITY · PI WYNN, JAMES LAWRENCE · 2013 to 2017
$875k
Regulation of Innate Immunity and Inflammation Through Nuclear ReprogrammingI01BX002750 · VA · VETERANS HEALTH ADMINISTRATION · PI HAWIGER, JACK J · 2016 to 2024
–
BLRD VA I01 BX002750NCI NIH HHS P30 CA068485NIDDK NIH HHS P30 DK058404NIGMS NIH HHS K08 GM106143
6 · The paper itself

Abstract

The rising tide of sepsis, a leading cause of death in the US and globally, is not adequately controlled by current antimicrobial therapies and supportive measures, thereby requiring new adjunctive treatments. Severe microvascular injury and multiple organ failure in sepsis are attributed to a "genomic storm" resulting from changes in microbial and host genomes encoding virulence factors and endogenous inflammatory mediators, respectively. This storm is mediated by stress-responsive transcription factors that are ferried to the nucleus by nuclear transport shuttles importins/karyopherins. We studied the impact of simultaneously targeting two of these shuttles, importin alpha 5 (Imp α5) and importin beta 1 (Imp β1), with a cell-penetrating Nuclear Transport Modifier (NTM) in a mouse model of polymicrobial sepsis. NTM reduced nuclear import of stress-responsive transcription factors nuclear factor kappa B, signal transducer and activator of transcription 1 alpha, and activator protein 1 in liver, which was also protected from sepsis-associated metabolic changes. Strikingly, NTM without antimicrobial therapy improved bacterial clearance in blood, spleen, and lungs, wherein a 700-fold reduction in bacterial burden was achieved while production of proinflammatory cytokines and chemokines in blood plasma was suppressed. Furthermore, NTM significantly improved thrombocytopenia, a prominent sign of microvascular injury in sepsis, inhibited neutrophil infiltration in the liver, decreased L-selectin, and normalized plasma levels of E-selectin and P-selectin, indicating reduced microvascular injury. Importantly, NTM combined with antimicrobial therapy extended the median time to death from 42 to 83 hours and increased survival from 30% to 55% (p = 0.022) as compared to antimicrobial therapy alone. This study documents the fundamental role of nuclear signaling mediated by Imp α5 and Imp β1 in the mechanism of polymicrobial sepsis and highlights the potential for targeting nuclear transport as an adjunctive therapy in sepsis management.

Indexed as

Active Transport, Cell Nucleusalpha KaryopherinsAnimalsAnti-Infective Agentsbeta KaryopherinsCell-Penetrating PeptidesChemokinesCytokinesDisease Models, AnimalFemaleLiverMiceMice, Inbred C57BLNeutrophilsNuclear ProteinsSelectinsalpha KaryopherinsAnti-Infective Agentsbeta KaryopherinsCell-Penetrating PeptidesChemokinescSN50.1 peptideCytokinesKPNA1 protein, mouseKpnb1 protein, mouseNuclear ProteinsSelectinsTranscription Factor RelA

Identifiers

PMID28628637
PMCPMC5476269
OpenAlexW2657047917

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.